We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · January 24, 2021

Axitinib Plus Pembrolizumab in Advanced RCC

European Journal of Cancer


Additional Info

European Journal of Cancer
Axitinib Plus Pembrolizumab in Patients With Advanced Renal-Cell Carcinoma: Long-Term Efficacy and Safety From a Phase Ib Trial
Eur. J. Cancer 2021 Mar 01;145(xx)1-10, MB Atkins, ER Plimack, I Puzanov, MN Fishman, DF McDermott, DC Cho, U Vaishampayan, S George, JC Tarazi, W Duggan, R Perini, M Thakur, KC Fernandez, TK Choueiri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading